MedTrace Logo

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

NCT01392989 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-05-07

Study results available
· View outcomes & findings →

Summary

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

Conditions

  • Neural Tube Defects
  • Anemia
  • Leukemia, Myeloid
  • Bone Marrow Transplant Failure
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Disorders

Interventions

DRUG

CIK cells

Standard of care

DRUG

Cyclosporine

5 mg/kg, po

DRUG

Mycophenolate Mofetil

15 mg/kg, oral

DRUG

Thymoglobulin

7.5 mg/kg, IV

RADIATION

Total Lymphoid Irradiation (TLI)

Sponsors & Collaborators

  • Everett Meyer

    lead OTHER

Principal Investigators

  • Everett Meyer, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2016-06-07
Completion
2017-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392989 on ClinicalTrials.gov